Silence Therapeutics
SLN
27 hedge funds and large institutions have $276M invested in Silence Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
50% more capital invested
Capital invested by funds: $183M → $276M (+$92.4M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.02% less ownership
Funds ownership: 17.33% → 17.31% (-0.02%)
7% less funds holding
Funds holding: 29 → 27 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
+$1.91M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$1.2M |
| 3 |
Morgan Stanley
New York
|
+$731K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$387K |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.36M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$786K |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$692K |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$273K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$226K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $60.3K | – | – | – |
|
|
SPIA
27
Steward Partners Investment Advisory
New York
| $1.52K | – | – | – |
|
|
UOC
28
UBS O'Connor
Chicago,
Illinois
| – | -$786K | -79,636 | Closed |
|
|
GPP
29
Great Point Partners
Greenwich,
Connecticut
| – | -$692K | -68,915 | Closed |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$226K | -22,851 | Closed |
|
|
CSS
31
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$5K | -500 | Closed |
|
SLN Hedge Fund Activity: Q4 2022 in Review
27 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2022, worth a combined $276M — up 50% from $183M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SLN and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was M28 Capital Management, opening a new position worth an estimated $1.91M. The largest seller was Point72 Asset Management, cutting an estimated $2.36M.
- 27 institutional investors held Silence Therapeutics (SLN) as of Q4 2022, down from 29 in Q3 2022.
- Funds reported $276M of Silence Therapeutics stock for Q4 2022, up 50% quarter-over-quarter.
- 2 funds opened new Silence Therapeutics positions in Q4 2022 and 4 closed out, a net change of -2 holders.
- The largest Silence Therapeutics buyer in Q4 2022 was M28 Capital Management, an estimated $1.91M added.
- The largest Silence Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $2.36M sold.
Based on aggregated 13F filings for Q4 2022.